Serelaxin inhibits LPS-induced inflammatory cytokines secretion
To assess the anti-inflammatory effects of serelaxin on LPS-induced
inflammation, the inhibitory effect of serelaxin on the products of
inflammatory cytokines treated with LPS was tested. Compared with the
control group, the results illustrated that secretion of IL-1β, IL-6 and
TNF-α increased significantly, IL-10 decreased marked with LPS treated.
Nonetheless, treatment of serelaxin suppressed LPS-induced IL-1β, IL-6
and TNF-α secretion markedly (Fig. 5). The results of mRNA showed that
compared with control group, the mRNA expression of IL-1β, IL-6 and
TNF-α increased significantly, IL-10 mRNA decreased in LPS stimulation.
However, treatment of serelaxin inhibited LPS-induced IL-1ß, IL-6 and
TNF-α mRNA expression significantly, and IL-10 in LPS-induced cells
increased significantly in serelaxin (Fig. 5). Additionally, GW9662, a
PPAR-γ inhibitor, lessened the inhibitory effect of serelaxin on IL-1ß,
IL-6 and TNF-α production.